|
De Novo and Secondary Myelodysplastic Syndrome
Current Clinical Trials
Standard treatment options:
- Myeloablative allogeneic stem cell transplantation.
- Erythropoeitic growth factors, in patients with endogenous erythropoietin levels less than 500 u/mL.
- 5-azacitidine or decitabine.
- Lenalidomide for patients with deletions of chromosome 5q31.
- Antithymocyte globulin.
Treatment options under clinical evaluation:
- Nonmyeloablative stem cell transplantation.
- Farnesyl transferase inhibitors (tipifarnib and lonafarnib).
- Combination regimens.
- Thrombopoietic agents.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with de novo myelodysplastic syndromes 1 and secondary myelodysplastic syndromes 2. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 3.
|
